Video

William G. Wierda on the Treatment of CLL

Author(s):

William G. Wierda

CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals.

William G. Wierda, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the treatment of chronic lymphocytic leukemia (CLL). CURE spoke with Wierda at the 2015 Chemotherapy Foundation Symposium, a meeting of over 1,000 oncologists and oncology professionals in early November.

Related Videos
Image of Dr. Braun.
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Azka Ali is a medical oncologist at the Cleveland Clinic Taussig Cancer Institute, in Ohio.
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Related Content
Illustration of blood cells.
January 21st 2025

Glucarpidase May Improve Renal Outcomes in Lymphoma, Leukemia

Ryan Scott
Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Chester Freeman was diagnosed with bladder cancer and most recently with chronic lymphocytic leukemia (CLL)!
January 10th 2025

Learning to ‘Let it Be’ After Poor Test Results

Chester Freeman
When I recognize my frustration and dissapointment with the test results for my chronic lymphocytic leukemia, I find comfort in listening to music.